ODDITY Tech Ltd. (ODD) reports Q1 2023 earnings with a 26% revenue decline. Management focuses on strategic initiatives and expects positive EBITDA for the year.

Key Takeaways

• Net revenue for Q1 2023 declined by 26%, slightly better than the anticipated 30% decline.
• First orders dropped approximately 50%, contributing to the revenue downturn.
• Gross margin stood at 69.7%, a decrease of about 520 basis points year-over-year.
• Adjusted EBITDA showed a loss of $7 million, with an expectation of positive EBITDA for the full year.
• The company executed a share buyback program, repurchasing about 6 million shares for $82 million, reducing shares outstanding by 10%.

Financial Performance

In its Q1 2023 earnings call, ODDITY Tech Ltd. reported a net revenue decline of 26%, which was slightly better than the expected 30% drop. This decrease in revenue was primarily driven by a significant 50% drop in first orders, a result of higher customer acquisition costs (CPA). Repeat orders also saw a decline of around 15%, highlighting challenges in retaining customer loyalty amid the current market conditions.

The company's average order value (AOV) experienced a low single-digit decline due to a shift in product mix towards its Spoiled Child brand versus Il Makiage. The gross margin for the quarter was reported at 69.7%, reflecting a compression of approximately 520 basis points year-over-year. This decline was attributed to changes in product mix and lower average order values.

Adjusted EBITDA was reported as a negative $7 million, primarily impacted by the elevated CPA and operational adjustments aimed at recalibrating the company’s marketing algorithms. The adjusted diluted earnings per share (EPS) came in at a negative $0.17, while the company maintained a strong cash position with $667 million in cash, cash equivalents, and investments.

Strategic Initiatives

During the earnings call, management highlighted several important strategic initiatives aimed at refining their operational approach. One of the major focuses is on their Methodic product line, which includes 28 prescription and non-prescription products designed to maximize efficacy in dermatological treatments. The company is also optimistic about its progress tracking app, which has shown strong user engagement and demand indicators.

In terms of product innovation, ODDITY is advancing its OT Labs to push ingredient innovation in beauty and wellness sectors. The company launched two new products in the Methodic lineup: Durexide Topical Eczema treatment and Zarolac, aimed at treating eczema and atherosclerosis, respectively. These products utilize proprietary molecules aimed at enhancing efficacy while minimizing side effects, showcasing the company's commitment to innovation.

Management also reiterated the importance of the Try Before You Buy program, which remains a core part of their acquisition strategy. This program aims to enhance customer experience by allowing potential buyers to sample products before committing to a purchase.

Future Outlook

Looking ahead, management expressed cautious optimism regarding the financial outlook. For the second quarter of 2023, ODDITY anticipates a net revenue decline between 25% and 30% year-over-year. However, the company expects to achieve positive adjusted EBITDA in the range of $8 million to $10 million. Management emphasized the importance of continued investment in acquisition efforts despite the current high CPA, indicating that these efforts are necessary for the long-term normalization of customer acquisition channels.

The company is also focused on resolving the technical challenges that have impacted their advertising efficiency. They are hopeful that improvements seen in May will continue, suggesting a potential recovery in customer acquisition metrics. Management noted that the overall user acquisition activity in the first half of the year will continue to affect repeat sales throughout the remainder of 2023.

Closing Assessment

In conclusion, ODDITY Tech Ltd. faces significant challenges in the current market environment, with a notable decline in revenues driven by first-order difficulties and elevated customer acquisition costs. However, the company's strong cash position, ongoing product innovation, and strategic initiatives suggest a pathway towards recovery. Management's focus on maintaining positive EBITDA for the year and their commitment to resolving technical issues will be crucial as they aim to return to a growth trajectory. Investors should keep an eye on the upcoming quarters to assess the effectiveness of these strategies and the overall market response.

This analysis is based on public earnings call materials and is not investment advice.